Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Failing at Least Second-line Therapy
CTR20201425Phase 2Terminated
- Sponsor
- Junshi Biosciences
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Junshi Biosciences. Started Aug 2020; status: terminated.
02
Drugs
toripalimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20201425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201425.